DOI: http://dx.doi.org/10.18203/2394-6040.ijcmph20210237

Adverse drug reactions among new sputum positive pulmonary tuberculosis patients on daily treatment regimen: a prospective study from Haryana, India

Chalamcharla M. Manjula, J. P. Majra

Abstract


Background: Daily regimen anti-tuberculosis treatment was adopted by Revised National Tuberculosis Control Programme (RNTCP) as a step to achieve tuberculosis elimination by 2025 in India. The change was implemented prior to completion of pilot study, which necessitated this study to note the self-reported Adverse Drug Reactions (ADRs).

Methods: A prospective study with concurrent sampling design was carried on from June 2018 to June 2020 in the state of Haryana, India. Pre-tested semi-structured schedule was used to collect data based on RNTCP outcome definitions through two monthly (four visits) home visits. Mean±standard deviation, percentage, proportion and chi-square test was used. The p-value of <0.05 was considered as statistically significant.

Results: Amongst 122 study participants 74 (60.7%) were males and 48 (39.3%) were females with mean age of 39.4±18.9 years. Majority were urban residents 87 (71.3%) and 35 (28.7%) rural residents. There were 25 (20.5%) tobacco smokers, nine (7.4%) alcohol consumers, and three (2.5%) smokeless tobacco users. Forty-five participants had ADRs and 54 ADR events had occurred, but none required change in treatment regimen. Sixteen (13.1%) reported loss of appetite followed by 10 (8.2%), flu-like symptoms, eight (6.6%) nausea, seven (5.7%) pain in joints, three (2.5%) abdomen pain, three (2.5%) headache, two (1.6%) itching and rash, one (0.8%) burning in hands and feet and one (0.8%) giddiness. Daily regimen ADR cases (36.9%) and events (44.3%) when comparatively higher than intermittent regimen (25.6%).

Conclusions: The ADRs cases and events had occurred in higher proportion but were mild and hence did not require any regimen change.

 


Keywords


Adverse drug reactions, Anti-tuberculosis treatment, Daily regimen, New sputum positive, Pulmonary tuberculosis

Full Text:

PDF

References


WHO. Tuberculosis (TB). Geneva: World Health Organization; 2020. Available at https:// www. who. Int/ news- room/ fact -sheets/ detail / tuberculosis. Accessed on 9 June 2020.

WHO. Global tuberculosis report 2019. Geneva: World Health Organization. Available at https://apps.who.int/iris/bitstream/handle/10665/329368/9789241565714- eng.pdf?ua=1. Accessed on 20 June 2020.

Central TB Division. India TB report 2019. Available at https:// tbcindia. gov. in/ WriteReadData/India%20TB%20Report%202019.pdf. Accessed on 18 June 2020.

Jilani T, Avula A, Gondal A, Siddiqui A. Active Tuberculosis. Available at https:// www. ncbi.nlm.nih.gov/books/NBK513246/?report=printable. Accessed on 18 June 2020.

Skolnik R. Global health 101. 3rd edition. Burlington, MA: Jones and Bartlett Learning. 2016:331.

The World Bank. Implementation Plan, Phase II (October2005-September2010). New Delhi, Revised National TB Control Programme (RNTCP). 2005.

WHO. Global Tuberculosis Control 2009: Epidemiology, Strategy, Financing. Geneva, Switzerland: World Health Organization. Available at https:// apps. who. int/ iris/ bitstream/ handle/10665/44241/9789241598866_eng.pdf. Accessed on 20 June 2020.

World Health Organization, Regional Office for South-East Asia. New Delhi (India); Joint Tuberculosis Programme Review. 2006. Available at https:/ /apps. who. int/ iris/ handle/ 10665/205401. Accessed on 25 June 2020.

Anti-tuberculosis drug resistance in the world: Fourth Global Report. Geneva, World Health Organization, 2008 WHO/HTM/TB/2008.394. Available at https://www.who.int/tb/publications/tb-drugresistance-fourthreport/en/. Accessed on 25 June 2020.

Rao P, Chawla K, Shenoy VP, Mukhopadhyay C, Brahmavar V, Kamath A, et al. Study of drug resistance in pulmonary tuberculosis cases in south coastal Karnataka. J Epidemiol Global Health. 2015;5(3):275-81.

Kanabus A. TB treatment in India - drug susceptible and drug resistant - TB Facts. TB Facts. 2020. Available at https://tbfacts.org/tb- treatment-india/. Accessed on 19 April 2020.

Maciel EL, Guidoni LM, Favero JL. Adverse effects of the new tuberculosis treatment regimen recommended by the Brazilian Ministry of Health. J Bras Pneumol. 2010;36:232-38.

Central Tuberculosis Division Government of India. Central TB Division; 2018. Prevention and management of adverse reactions associated with anti-tuberculosis drugs 2016. Available at https://www.tbcindia.gov.in/WriteReadData/Prevention%20and%20Management%20of%20Adverse%20Reaction/files/assets/common/downloads/publication.pdf. Accessed on 18 June 2020.

A rapid assessment of gender and tuberculosis in India. UNOPS. 2018;28-36. Available at http:// www.stoptb.org/ assets/ documents/ communities/ CRG/ TB%20Gender%20Asses sment%20India.pdf. Accessed on 20 May 2020.

Sudha G, Beena ET, Jawahar MS, Selvi K, Sivasubramaniam S, Weiss M. Perceptions of gender and tuberculosis in a south Indian urban community. Indian J Tuberc. 2008;55:9-14.

Júnior FS, Francisco PM, Nogueira PA. Knowledge, attitudes and practices regarding tuberculosis among transgender individuals in the city of São Paulo, Brazil. Ciencia Saude Coletiva. 2019;24:3025-36.

Mukerji R, Turan JM. Exploring manifestations of tb-related stigma experienced by women in Kolkata, India. Ann Glob Health. 2018;84(4):727.

Bates MN, Khalakdina A, Pai M, Chang L, Lessa F, Smith KR. Risk of tuberculosis from exposure to tobacco smoke: a systematic review and meta-analysis. Arch of Intern Med. 2007;167(4):335-42.

Bartacek A, Schütt D, Panosch B, Borek M, Rimstar® 4-FDC Study Group. Comparison of a four-drug fixed-dose combination regimen with a single tablet regimen in smear-positive pulmonary tuberculosis. Int J Tuberc Lung Dis. 2009;13(6):760-6.

Gopalan N, Santhanakrishnan RK, Palaniappan AN, Menon PA, Lakshman S, Chandrasekaran P, et al. Daily vs intermittent antituberculosis therapy for pulmonary tuberculosis in patients with HIV: a randomized clinical trial. JAMA Internal Medicine. 2018;178(4):485-93.

Sadiq S, Khajuria V, Tandon VR, Mahajan A, Singh JB. Adverse drug reaction profile in patients on anti-tubercular treatment alone and in combination with highly active antiretroviral therapy. J Clin Diag Res. 2015;9(10):FC01.

Asati D. Profile of adverse drug reactions in tb patients taking ATT. J Med Sci Clin Res. 2016;04(12):14589-92.

Dalal NP, Karandikar YS, Pandit VA. Safety evaluation of directly observed treatment short course (DOTS) regimen in a tertiary care hospital, Pune. Int J Basic Clin Pharmacol. 2014;3:369-76.

Mandal PK, Mandal A, Bhattacharyya SK. Comparing the daily versus the intermittent regimens of the anti-tubercular chemotherapy in the initial intensive phase in Non-HIV, sputum positive, pulmonary tuberculosis patients. J Clin Diagn Res. 2013;7(2):292-5.

Alladi MS. Tuberculosis. 2nd ed. New Delhi: Jaypee Brothers Medical Publisher (P) Ltd.; 2009:57.

Singh AK, Pant N. Adverse effects of first line antitubercular medicines on patients taking directly observed treatment short course: a hospital based study. Int J Med Public Health. 2014;4:354-8.